LIPOCINE INC. (NASDAQ:LPCN) Files An 8-K Other Events

Item 8.01

As reported in its Annual Report on Form 10-K filed on the date
hereof, on March 6, 2017, Lipocine Inc. (the Company) entered
into a Controlled Equity Offering^SM Sales Agreement,
dated March 6, 2017 (the Sales Agreement), with Cantor Fitzgerald
Co., as agent (Cantor Fitzgerald), to which the Company may issue
and sell shares of its common stock, $0.0001 par value per share,
having an aggregate offering price of up to $20.0 million (the
Shares) from time to time through Cantor Fitzgerald (the
Offering). The material terms of the Sales Agreement are
described in the Companys Annual Report on Form 10-K filed on the
date hereof. Also on March 6, 2017, the Company filed a
prospectus supplement with the Securities and Exchange Commission
in connection with the Offering (the Prospectus Supplement) under
its existing Registration Statement on Form S-3 (File No
333-199093), which became effective on October14, 2014 (the
Registration Statement).

Dorsey Whitney LLP, counsel to the Company, has issued a legal
opinion relating to the Shares. A copy of such legal opinion,
including the consent included therein, is attached as Exhibit
5.1 hereto.

The Shares will be sold to the Registration Statement, and
offerings of the Shares will be made only by means of the
Prospectus Supplement. This Current Report on Form 8-K shall not
constitute an offer to sell or solicitation of an offer to buy
these securities, nor shall there be any sale of these securities
in any state in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities law of such state or jurisdiction.

See Exhibit Index attached hereto.

About LIPOCINE INC. (NASDAQ:LPCN)

Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company’s additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip’ral promicellar drug delivery technology platform. Lip’ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.

LIPOCINE INC. (NASDAQ:LPCN) Recent Trading Information

LIPOCINE INC. (NASDAQ:LPCN) closed its last trading session down -0.12 at 3.88 with 113,622 shares trading hands.